11:16 AM EST, 12/23/2024 (MT Newswires) -- Cosciens Biopharma ( CSCI ) was at last look was down 3.3% Monday after saying that it is repositioning itself as a life sciences business offering natural based products.

This follows last August's conclusion of a Phase 3 study evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency (CGHD) that had had failed to meet its primary endpoint. While maintaining the current commercial indication for the use of macimorelin for the diagnosis of Adult Growth Hormone Deficiency (AGHD), the company will not make any future investments in macimorelin for the diagnosis of CGHD.

To that end, Dr. Nicola Ammer, Chief Medical Officer, will finish up on March 31, 2025.

Cosciens said the Phase 1 portion of the avenanthramides clinical trial, that is ongoing at the Montreal Heart Institute, has been completed with 72 subjects tested. No significant side effects were observed from ascending doses ranging from 30 mg to 960 mg.

The company expects the Phase 2a efficacy study will be initiated in the first quarter of next year, with expected completion in the third quarter.

Cosciens' avenanthramides tablets are being developed as an anti-inflammatory.

The company also said that its yeast beta glucan (YBG) powder product, is being finalized in capsule form with the goal to commercialize it as an immune booster in the second quarter of next year.

Cosciens will also be launching its oat beta glucan chewable bar (for cholesterol reduction) in the first quarter of 2025

Price: 3.79, Change: -0.13, Percent Change: -3.32